Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine

  • Olmeda, David
  • Cerezo-Wallis, Daniela
  • Riveiro-Falkenbach, Erica
  • Pennacchi, Paula C.
  • Contreras-Alcalde, Marta
  • Ibarz, Nuria
  • Cifdaloz, Metehan
  • Catena, Xavier
  • Calvo, Tonantzin G.
  • Cañón, Estela
  • Alonso-Curbelo, Direna
  • Suarez, Javier
  • Osterloh, Lisa
  • Graña-Castro, Osvaldo
  • Mulero, Francisca
  • Megías, Diego
  • Cañamero, Marta
  • Martínez-Torrecuadrada, Jorge Luis
  • Mondal, Chandrani
  • Di Martino, Julie
  • Lora, David
  • Martinez-Corral, Inés
  • Bravo-Cordero, José J.
  • Muñoz, Javier
  • Puig, Susana
  • Ortiz-Romero, Pablo
  • Rodriguez-Peralto, José L.
  • Ortega, Sagrario
  • Soengas, María S.
Cutaneous melanoma is a type of cancer with an inherent potential for lymph node colonization, which is generally preceded by neolymphangiogenesis1,2,3. However, sentinel lymph node removal does not necessarily extend the overall survival of patients with melanoma4,5. Moreover, lymphatic vessels collapse and become dysfunctional as melanomas progress6,7. Therefore, it is unclear whether (and how) lymphangiogenesis contributes to visceral metastasis. Soluble and vesicle-associated proteins secreted by tumours and/or their stroma have been proposed to condition pre-metastatic sites in patients with melanoma8,9,10,11,12,13,14. Still, the identities and prognostic value of lymphangiogenic mediators remain unclear2,14. Moreover, our understanding of lymphangiogenesis (in melanomas and other tumour types) is limited by the paucity of mouse models for live imaging of distal pre-metastatic niches15. Injectable lymphatic tracers have been developed7, but their limited diffusion precludes whole-body imaging at visceral sites16. Vascular endothelial growth factor receptor 3 (VEGFR3) is an attractive ‘lymphoreporter’17 because its expression is strongly downregulated in normal adult lymphatic endothelial cells, but is activated in pathological situations such as inflammation and cancer17,18. Here, we exploit this inducibility of VEGFR3 to engineer mouse melanoma models for whole-body imaging of metastasis generated by human cells, clinical biopsies or endogenously deregulated oncogenic pathways. This strategy revealed early induction of distal pre-metastatic niches uncoupled from lymphangiogenesis at primary lesions. Analyses of the melanoma secretome and validation in clinical specimens showed that the heparin-binding factor midkine is a systemic inducer of neo-lymphangiogenesis that defines patient prognosis. This role of midkine was linked to a paracrine activation of the mTOR pathway in lymphatic endothelial cells. These data support the use of VEGFR3 reporter mice as a ‘MetAlert’ discovery platform for drivers and inhibitors of metastasis., M.S.S. is funded by grants from the Spanish Ministry of Economy and Innovation (project SAF2014-56868-R), the Asociación Española Contra el Cáncer (AECC), the Worldwide Cancer Research, an Established Investigator Award from the Melanoma Research Alliance (MRA), and a L’Oréal Paris USA-MRA Team Science Award for Woman in Scientific Research. The CNIO Proteomics Unit belongs to ProteoRed, PRB2-ISCIII, supported by grant PT13/0001. N.I. and J.M. are funded by SAF2013-45504-R (MINECO). J.M. is also supported by Ramon y Cajal Programme (MINECO) RYC-2012-10651. J.L.R.-P and P.O.-R are funded by grants FIS 2014/1737, 11/02568 and FIS 2014/01784, 11/1759, respectively, from the Spanish Ministry of Health. F.M. is funded by the AMIT Project/CDTI/CENIT Programme (MICINN), S.O. by SAF2013-44866-R (MINECO), and J.J.B.-C. by an NCI K22CA196750 grant and the TCI Young Scientist Cancer Research Award JJR Fund (P30 CA196521). J.D.M. is the recipient of a postdoctoral fellowship from the ARC Foundation and E.R.-F. from Fundación Científica de la Asociación Española Contra el Cáncer. D.C.-W. is the recipient of a predoctoral fellowship from Fundación La Caixa, and M.C.-A. and X.C. are recipients of the Immutrain Marie Skłodowska-Curie ITN Grant., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Chemical Screen Identifies Compounds Capable of Selecting for Haploidy in Mammalian Cells

  • Olbrich, Teresa
  • Vega-Sendino, María
  • Murga, Matilde
  • Cárcer, Guillermo de
  • Malumbres, Marcos
  • Ortega, Sagrario
  • Ruiz, Sergio
  • Fernández-Capetillo, Óscar
© 2019 The Authors., The recent availability of somatic haploid cell lines has provided a unique tool for genetic studies in mammals. However, the percentage of haploid cells rapidly decreases in these cell lines, which we recently showed is due to their overgrowth by diploid cells present in the cultures. Based on this property, we have now performed a phenotypic chemical screen in human haploid HAP1 cells aiming to identify compounds that facilitate the maintenance of haploid cells. Our top hit was 10-Deacetyl-baccatin-III (DAB), a chemical precursor in the synthesis of Taxol, which selects for haploid cells in HAP1 and mouse haploid embryonic stem cultures. Interestingly, DAB also enriches for diploid cells in mixed cultures of diploid and tetraploid cells, including in the colon cancer cell line DLD-1, revealing a general strategy for selecting cells with lower ploidy in mixed populations of mammalian cells., Research was funded by Fundación Botín, Banco Santander through its Santander Universities Global Division, and by grants from MINECO (SAF2014-57791-REDC and SAF2014-59498-R to O.F.-C., SAF-2013- 44866-R to S.O., and SAF2013-49147-P and SAF2016-80874-P to S.R.; projects that were co-financed with ERDF-EU funds) and the European Research Council (ERC-617840). Research at the G.d.C. laboratory is funded by the AECC Scientific Foundation (LABAE16017DECA).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Global hyperactivation of enhancers stabilizes human and mouse naive pluripotency through inhibition of CDK8/19 mediator kinases

  • Lynch, Cian J.
  • Bernad, Raquel
  • Martínez-Val, Ana
  • Shahbazi, Marta N.
  • Nóbrega-Pereira, Sandrina
  • Calvo, Isabel
  • Blanco-Aparicio, Carmen
  • Tarantino, Carolina
  • Garreta, Elena
  • Richart-Ginés, Laia
  • Alcazar, Noelia
  • Graña-Castro, Osvaldo
  • Gómez-López, Gonzalo
  • Aksoy, Irene
  • Muñoz-Martín, Maribel
  • Martinez, Sonia
  • Ortega, Sagrario
  • Prieto, Susana
  • Simboeck, Elisabeth
  • Camasses, Alain
  • Stephan-Otto Attolini, Camille
  • Fernández, Agustín F.
  • Sierra, Marta I.
  • Fraga, Mario F.
  • Pastor, Joaquín
  • Fisher, Daniel
  • Montserrat, Núria
  • Savatier, Pierre
  • Muñoz, Javier
  • Zernicka-Goetz, Magdalena
  • Serrano, Manuel
Pluripotent stem cells (PSCs) transition between cell states in vitro, reflecting developmental changes in the early embryo. PSCs can be stabilized in the naive state by blocking extracellular differentiation stimuli, particularly FGF–MEK signalling. Here, we report that multiple features of the naive state in human and mouse PSCs can be recapitulated without affecting FGF–MEK signalling or global DNA methylation. Mechanistically, chemical inhibition of CDK8 and CDK19 (hereafter CDK8/19) kinases removes their ability to repress the Mediator complex at enhancers. CDK8/19 inhibition therefore increases Mediator-driven recruitment of RNA polymerase II (RNA Pol II) to promoters and enhancers. This efficiently stabilizes the naive transcriptional program and confers resistance to enhancer perturbation by BRD4 inhibition. Moreover, naive pluripotency during embryonic development coincides with a reduction in CDK8/19. We conclude that global hyperactivation of enhancers drives naive pluripotency, and this can be achieved in vitro by inhibiting CDK8/19 kinase activity. These principles may apply to other contexts of cellular plasticity., M.N.S. was funded by a Leverhulme Trust early career fellowship. Work in the laboratory of M.Z.-G. was funded by the Wellcome Trust (098287/Z/12/Z) and the European Research Council (ERC) (669198). I.C. was funded by the Secretaria d’Universitats i Recerca de la Generalitat de Catalunya and European Social Fund. I.A. and P.S. were supported by the Fondation pour la Recherche Medicale (DEQ20170336757), Infrastructure Nationale en Biologie et Santé INGESTEM (ANR-11-INBS-0009), IHU-B CESAME (ANR-10-IBHU-003), LabEx REVIVE (ANR-10-LABX-73), LabEx DEVweCAN (ANR-10-LABX-0061) and LabEx CORTEX (ANR-11-LABX-0042) of University of Lyon within the programme ‘Investissements d’Avenir’ (ANR-11-IDEX-0007). Research by J.P., S.M. and C.B.-A. was supported in part by a grant from the Spanish Ministry of Economy and Competitiveness (SAF2013-44267-R) and by the CNIO. Work in the laboratory of D.F. was funded by the Institut National du Cancer (PLBIO10-068 and PLBIO15-005) and the Ligue National Contre le Cancer (EL2018.LNCC/DF). Work in the laboratory of N.M. was funded by the ERC, under the European Union Horizon 2020 research and innovation programme (StG-2014–640525_REGMAMKID), the Spanish Association Against Cancer (AECC/LABAE16006), Carlos III Health Institute (Red TerCel, CardioCel, RD16/0011/0027), Ministry of Economy and Competitiveness (MINECO) projects SAF2017–89782-R, SAF2015–72617-EXP and RYC-2014–16242, and the CERCA/Government of Catalonia (2017 SGR 1306). Work in the laboratory of S.O. was funded by SAF2013–44866-R from MINECO Spain. Work in the laboratory of M.F.F. was funded by Plan Nacional de I+D+I 2013–2016/FEDER (PI15/00892, to M.F.F. and A.F.F.); the ISCIII-Subdireccion General de Evaluación y Fomento de la Investigación and Plan Nacional de I+D+I 2008–2011/FEDER (CP11/00131, to A.F.F.); IUOPA (to M.I.S.); and the Asturias Regional Government (GRUPIN14–052, to M.F.F.). The IUOPA is supported by the Obra Social Liberbank-Cajastur, Spain. Work in the laboratory of M.S. was funded by the CNIO, the IRB and by grants from Spanish Ministry of Economy co-funded by the European Regional Development Fund (SAF2017-82613-R), ERC (ERC-2014-AdG/669622), Botin Foundation, Banco Santander (Santander Universities Global Division), laCaixa Foundation and Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement of Catalonia (Grup de Recerca consolidat 2017 SGR 282)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Transient exposure to miR‐203 enhances the differentiation capacity of established pluripotent stem cells

  • Salazar‐Roa, María
  • Trakala, Marianna
  • Álvarez-Fernández, Mónica
  • Valdés‐Mora, Fátima
  • Zhong, Cuiqing
  • Muñoz, Jaime
  • Yu, Yang
  • Peters, Timothy J.
  • Graña‐Castro, Osvaldo
  • Serrano, Rosa
  • Zapatero-Solana, Elisabet
  • Abad, María
  • Bueno, María José
  • Gómez de Cedrón, Marta
  • Fernández-Piqueras, José
  • Serrano, Manuel
  • Blasco, María A.
  • Wang, Da‐Zhi
  • Clark, Susan J.
  • Izpisua‐Belmonte, Juan Carlos
  • Ortega, Sagrario
  • Malumbres, Marcos
Full differentiation potential along with self‐renewal capacity is a major property of pluripotent stem cells (PSCs). However, the differentiation capacity frequently decreases during expansion of PSCs in vitro. We show here that transient exposure to a single microRNA, expressed at early stages during normal development, improves the differentiation capacity of already‐established murine and human PSCs. Short exposure to miR‐203 in PSCs (miPSCs) induces a transient expression of 2C markers that later results in expanded differentiation potency to multiple lineages, as well as improved efficiency in tetraploid complementation and human–mouse interspecies chimerism assays. Mechanistically, these effects are at least partially mediated by direct repression of de novo DNA methyltransferases Dnmt3a and Dnmt3b, leading to transient and reversible erasure of DNA methylation. These data support the use of transient exposure to miR‐203 as a versatile method to reset the epigenetic memory in PSCs, and improve their effectiveness in regenerative medicine., M.S.R. was supported by the Asociación Española contra el Cáncer (AECC; 2012 AIOA120833SALA and 2018 INVES18005SALA) and a Juan de la Cierva contract from the Ministry of Science, Innovation and Universities (MICIU). M.T. was supported by Fundación La Caixa. M.A.F. was supported by MICIU (SAF2014‐60442‐JIN). J.F.P. was funded by MICIU (RTI2018‐093330‐B/FEDER‐EU), Ramón Areces Foundation (CIVP19S7917), CAM (B2017/BMD‐3778), and AECC (2018, PROYE18054PIRI). F.V.M was supported by the National Breast Cancer Foundation/Cure Cancer Australia Foundation Postdoctoral Training Fellow. Work in S.J.C laboratory was supported by the National Health and Medical Research Council (NHMRC 1063560). M.A.B. laboratory is funded by SAF2013‐45111‐R from MICIU, Fundación Botín and Banco Santander, and Worldwide Cancer Research (WCR16‐1177). Work in S.O. laboratory was funded by MICIU grant (SAF2013‐44866‐R). Work in the M.M. laboratory was supported by grants from the MICIU (RTI2018‐095582‐B‐I00, RED2018‐102723‐T, and SAF2017‐92729‐EXP), and the iLUNG Programme (B2017/BMD‐3884) from the Comunidad de Madrid. The CNIO is a Severo Ochoa Centers of Excellence (MICIU award SEV‐2015‐0510)., Peer reviewed